[go: up one dir, main page]

MA30624B1 - Vaccin anti-grippal - Google Patents

Vaccin anti-grippal

Info

Publication number
MA30624B1
MA30624B1 MA31612A MA31612A MA30624B1 MA 30624 B1 MA30624 B1 MA 30624B1 MA 31612 A MA31612 A MA 31612A MA 31612 A MA31612 A MA 31612A MA 30624 B1 MA30624 B1 MA 30624B1
Authority
MA
Morocco
Prior art keywords
influenza
pandemic
outbreak
tocopherol
relates
Prior art date
Application number
MA31612A
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0618195A external-priority patent/GB0618195D0/en
Priority claimed from GB0619090A external-priority patent/GB0619090D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA30624B1 publication Critical patent/MA30624B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations de vaccin antigrippal monovalent et des régimes de vaccination d'immunisation contre la grippe, leur utilisation médicale, en particulier leur utilisation pour augmenter les réponses immunitaires à divers antigènes, et leurs procédés de préparation. L'invention concerne en particulier des compositions immunogènes antigrippales monovalentes comprenant un antigène grippal ou une préparation d'antigène provenant de la souche du virus de la grippe qui est associée à l'éclosion d'une pandémie ou qui présente le potentiel d'être associée à l'éclosion d'une pandémie, en combinaison avec un adjuvant sous la forme d'une émulsion d'huile dans l'eau comprenant une huile métabolisable, un stérol ou un tocophérol tel qu'un alpha-tocophérol et un agent émulsifiant.
MA31612A 2006-07-17 2009-02-04 Vaccin anti-grippal MA30624B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83143706P 2006-07-17 2006-07-17
GB0618195A GB0618195D0 (en) 2006-09-15 2006-09-15 Influenza vaccine
GB0619090A GB0619090D0 (en) 2006-09-27 2006-09-27 Influenza vaccine

Publications (1)

Publication Number Publication Date
MA30624B1 true MA30624B1 (fr) 2009-08-03

Family

ID=37909516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31612A MA30624B1 (fr) 2006-07-17 2009-02-04 Vaccin anti-grippal

Country Status (14)

Country Link
US (4) US9278127B2 (fr)
EP (1) EP2043682B1 (fr)
JP (1) JP5639760B2 (fr)
KR (1) KR101696727B1 (fr)
CO (1) CO6150191A2 (fr)
CR (1) CR10559A (fr)
EA (1) EA200900024A1 (fr)
HR (2) HRP20140488T1 (fr)
IL (1) IL196024A0 (fr)
MA (1) MA30624B1 (fr)
MX (1) MX2009000660A (fr)
NO (1) NO20090062L (fr)
PL (1) PL2043682T3 (fr)
WO (1) WO2008009309A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU2006226459A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
KR20090016704A (ko) 2006-06-15 2009-02-17 노파르티스 아게 보조제-보존 수회-투여 인플루엔자 접종 요법
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2268309B1 (fr) 2008-03-18 2015-01-21 Novartis AG Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe
CA2729248A1 (fr) 2008-06-25 2009-12-30 Novartis Ag Reactions rapides a des immunisations de rappel retardees
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
EA201290897A1 (ru) * 2010-03-11 2013-03-29 Иммьюн Дизайн Корп. Вакцины для пандемического гриппа
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
EP2578974A1 (fr) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Chaîne de traitement pour la production de particules lyophilisées
GB201205189D0 (en) 2012-03-23 2012-05-09 Glaxosmithkline Biolog Sa Novel medical use
CN105612250A (zh) 2013-10-07 2016-05-25 诺华股份有限公司 经处理的滤器
CN107073350B (zh) 2014-07-21 2019-11-15 赛诺菲巴斯德股份公司 用于产生液滴的液体给送装置
KR101729387B1 (ko) 2015-04-17 2017-04-21 경희대학교 산학협력단 곤충세포 발현시스템을 이용한 인플루엔자 백신 소재 ｍ1-ｍ2-ｎａ-ｈａ 바이러스 유사 입자의 제조방법
WO2016210093A1 (fr) * 2015-06-24 2016-12-29 Sanofi Pasteur, Inc. Méthodes d'utilisation du vaccin de la grippe pour la prévention de la pneumonie
GB201710414D0 (en) 2017-06-29 2017-08-16 Univ Nottingham Chemotherapy
CA3080656A1 (fr) 2017-10-30 2019-05-09 Baxalta GmbH Detergents compatibles avec l'environnement pour l'inactivation de virus enveloppes de lipides
CN111629751B (zh) * 2018-01-22 2025-02-21 美国政府(由卫生和人类服务部的部长所代表) 广泛保护性灭活流感病毒疫苗
IL278096B2 (en) * 2018-04-18 2025-03-01 Biomadison Inc Methods for determining vaccine potency
KR102103638B1 (ko) * 2018-06-01 2020-04-22 연세대학교 산학협력단 저온 적응된 약독화 바이러스를 이용한 유니버설 독감 백신
WO2022005893A1 (fr) * 2020-06-29 2022-01-06 Seqirus UK Limited Stocks de vaccins adaptatifs
WO2025019631A1 (fr) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Compositions immunogènes contenant un virus de la grippe a inactivé et un adjuvant oligonucléotidique cpg et leurs utilisations

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
EP0382271B1 (fr) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols comme adjuvants de vaccins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5969109A (en) 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
DE4220757A1 (de) 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JPH08506592A (ja) 1993-02-19 1996-07-16 スミスクライン・ビーチャム・コーポレイション ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
AU6141094A (en) 1993-02-19 1994-09-14 Smithkline Beecham Biologicals (Sa) Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3836874B2 (ja) 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
HU225844B1 (en) 1998-05-07 2007-10-29 Corixa Corp Adjuvant composition and its use
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
WO2000050006A2 (fr) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions a macromolecules et microparticules adsorbees
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
OA12168A (en) 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
EP1201250A1 (fr) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition immunogène contenant des antigènes de plasmodium spécifiques des stades hépatiques
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
CA2478930A1 (fr) 2002-04-01 2003-10-16 Euro-Celtique, S.A. Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene
US20050106178A1 (en) 2003-01-30 2005-05-19 Chiron Corporation Adjuvanted influenza vaccine
DE202005022108U1 (de) * 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
US7330082B2 (en) 2004-08-23 2008-02-12 Texas Instruments Incorporated Oscillator system, method of providing a resonating signal and a communications system employing the same
AU2006226459A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20090028903A1 (en) 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US20090304742A1 (en) * 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
DE06808434T1 (de) * 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsionen mit freiem wässrigen phasen tensid als adjuvans für spalt-grippeimpfstoffe
US20110180430A1 (en) * 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
EP2368572B1 (fr) * 2005-11-04 2020-03-04 Seqirus UK Limited Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
DK2422810T3 (da) 2006-07-17 2014-11-24 Glaxosmithkline Biolog Sa Influenzavaccine
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
JP2011506290A (ja) * 2007-12-06 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザ組成物

Also Published As

Publication number Publication date
US10555999B2 (en) 2020-02-11
US11564984B2 (en) 2023-01-31
MX2009000660A (es) 2009-04-08
US20200360507A1 (en) 2020-11-19
CO6150191A2 (es) 2010-04-20
NO20090062L (no) 2009-02-16
KR20090029851A (ko) 2009-03-23
EP2043682A1 (fr) 2009-04-08
US9943588B2 (en) 2018-04-17
EP2043682B1 (fr) 2014-04-02
US9278127B2 (en) 2016-03-08
IL196024A0 (en) 2011-08-01
HRP20141122T1 (hr) 2015-01-02
PL2043682T3 (pl) 2014-09-30
CR10559A (es) 2009-03-20
KR101696727B1 (ko) 2017-01-16
US20190054162A1 (en) 2019-02-21
US20160256537A1 (en) 2016-09-08
EA200900024A1 (ru) 2009-06-30
JP2009543816A (ja) 2009-12-10
WO2008009309A1 (fr) 2008-01-24
US20110243987A1 (en) 2011-10-06
HRP20140488T1 (hr) 2014-07-04
JP5639760B2 (ja) 2014-12-10

Similar Documents

Publication Publication Date Title
MA30624B1 (fr) Vaccin anti-grippal
MA29342B1 (fr) Nouvelle composition
MA30866B1 (fr) Vaccin
MA31381B1 (fr) Vaccin contre la grippe a emulsion huile dans l'eau
MA29601B1 (fr) Vaccin antipaludeen
RU2434638C2 (ru) Вакцина альфа токсоида с.perfringens
TW200716165A (en) Novel vaccine formulations
TR201809043T4 (tr) Sentetik adjuvan içeren aşı bileşimi.
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
BRPI0621886A8 (pt) composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré-pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza, de um vírus da influenza pandêmica ou preparação antigênica do mesmo, e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza
Jones et al. Protollin™: a novel adjuvant for intranasal vaccines
BRPI0413906A (pt) composições imunogênicas de hiv, kit e métodos relacionados
MA28035A1 (fr) Vaccin
Potter et al. Effect of priming on subsequent response to inactivated influenza vaccine
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
SG139618A1 (en) Influenza vaccine
SG160386A1 (en) Novel composition
MX2009010963A (es) Vacuna de influenza de emulsion de aceite en agua.
CY1115921T1 (el) Εμβολιο γριπης
UY29429A1 (es) Composición inmunogénica que contiene virus de la gripe o preparación antígena del mismo, sus usos y procedimientos de preparación.
FR3043558B1 (fr) Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
DOP2009000068A (es) Vacuna que comprende un adyuvante de emulsión de aceite en agua